Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on May 27, 2020. The registrant is a Delaware corporation with its principal executive offices in Cincinnati, Ohio. The filing primarily addresses regulatory disclosures and significant corporate events related to its product candidate, razuprotafib.
Key Financial Metrics
The filing does not contain a comprehensive financial statement or detailed metrics for revenue, profit, cash flow, margins, or total debt. However, it discloses a specific financial commitment:
- Financial Support Commitment: The Company agreed to provide approximately $1.5 million in financial support for the I-SPY COVID-19 study.
Other liquidity and debt figures are not provided in this specific document.
Material Changes and Events
The primary material event reported is the selection of the Company's product candidate, razuprotafib, for the I-SPY COVID-19 study. Key details include:
- Study Sponsor: Quantum Leap Healthcare Collaborative.
- Study Design: Phase 2 randomized, controlled, multicenter study with an adaptive design.
- Objective: To assess the therapeutic potential of razuprotafib for treating acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
- Company Role: Aerpio will supply quantities of razuprotafib and provide the aforementioned financial support.
Guidance, Outlook, and Risks
Management Commentary: The Company is furnishing a corporate presentation (Exhibit 99.2) for use in investor meetings beginning May 28, 2020. The filing explicitly states that the information in the presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties of clinical trials. The success of the I-SPY study is contingent on the adaptive design and the performance of razuprotafib in the trial setting.
Investor Verification Checklist
- Verify the specific terms of the $1.5 million financial support agreement for the I-SPY study.
- Review the attached corporate presentation (Exhibit 99.2) for updated operational outlooks, noting it is not a formal filing.
- Monitor the progress and interim results of the I-SPY COVID-19 study regarding razuprotafib's efficacy in treating ARDS.
- Confirm the Company's cash runway and liquidity position in subsequent filings (e.g., 10-Q or 10-K) as this 8-K does not provide full financial statements.